Northwest Biotherapeutics, Inc.

4800 Montgomery Lane
Suite 800
Bethesda,  MD  20814

United States
http://www.nwbio.com
  • Booth: 7152

NWBio is developing DCVax® dendritic cell-based therapeutic vaccines. The Company’s DCVax®-L for resectable solid tumors is in a 331-patient Phase III trial for newly diagnosed GBM and Phase II trials in combination with checkpoint inhibitor drugs are planned. The Company’s DCVax®-Direct for inoperable solid tumors has completed a 40-patient Phase I trial for diverse cancers; various Phase II trials are planned.


  •  
  •      
     

  •  
  •